Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 6, 2014, Pages 1197-1204

  Slusarz, Katherine M ^a   Merker, Vanessa L ^a   Muzikansky, Alona ^a   Francis, Sanjeev A ^a   Plotkin, Scott R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bevacizumab; Hypertension; Neurofibromatosis 2; Proteinuria; Toxicity

Indexed keywords

ANTIHYPERTENSIVE AGENT; BEVACIZUMAB;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHILD; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; EPENDYMOMA; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; MALE; MEAN ARTERIAL PRESSURE; NEURILEMOMA; NEUROFIBROMATOSIS; PRIORITY JOURNAL; PROTEINURIA; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINALYSIS;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; COHORT STUDIES; COMPASSIONATE USE TRIALS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEUROFIBROMATOSIS 2; PROTEINURIA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903818825     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2456-2     Document Type: Article

References (24)

1. Evans DG, Sainio M, Baser ME (2000) Neurofibromatosis type 2. J Med Genet 37:897-904 (Pubitemid 32002885)
2. Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361:358-367
3. Mautner VF, Nguyen R, Kutta H, Fuensterer C, Bokemeyer C, Hagel C, Friedrich RE, Panse J (2010) Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 12:14-18
4. Eminowicz GK, Raman R, Conibear J, Plowman PN (2011) Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy. J Laryngol Otol 126:79-82
5. Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG (2012) Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 33:1046-1052
6. Nazer B, Humphreys BD, Moslehi J (2011) Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 124:1687-1691
7. Hurwitz HI, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, Chen D, Rosen O (2013) Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist 18:273-280
8. Shah SR, Gressett Ussery SM, Dowell JE, Marley E, Liticker J, Arriaga Y, Verma U (2013) Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension. Ann Oncol 24:960-965
9. Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD (2010) Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol 30:591-601
10. Mulvihill JJ, Parry DM, Sherman JL, Pikus A, Kaiser-Kupfer MI, Eldridge R (1990) NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med 113:39-52 (Pubitemid 20196630)
11. Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DG (2002) Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 59:1759-1765 (Pubitemid 35424459)
12. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289:2560-2572 (Pubitemid 37430158)
13. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, Lefevre ML, Mackenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E (2013) 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA
14. Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, Ivy SP, Leier CV, Lindenfeld J, Liu G, Remick SC, Steingart R, Tang WH (2010) Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 102:596-604
15. Fangusaro J, Gururangan S, Poussaint TY, McLendon RE, Onar-Thomas A, Warren KE, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Jakacki R, Gajjar A, Goldman S, Pollack IF, Friedman HS, Boyett JM, Kun LE, Fouladi M (2013) Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a pediatric brain tumor consortium study (PBTC-022). Cancer 119:4180-4187
16. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S (2010) Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 23:460-468
17. Hornigold RE, Golding JF, Ferner RE, Ferner RE (2011) Neurofibromatosis 2: a novel risk factor for hypertension? Am J Med Genet A 155A:1721-1722
18. Miller K, Rugo HS, Cobleigh MA (2002) Phase III trial of capecitabine (Xeloda) plus bevacizumab (Avastin) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. Breast Cancer Res Treat 76:S37
19. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434 (Pubitemid 36910021)
20. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S (2009) Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 20:227-230
21. Osterlund P, Soveri LM, Isoniemi H, Poussa T, Alanko T, Bono P (2011) Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer 104:599-604
22. De SA, Carlomagno C, Pepe S, Bianco R, De PS (2011) Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol 68:1207-1213
23. Bono P, Elfving H, Utriainen T, Osterlund P, Saarto T, Alanko T, Joensuu H (2009) Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol 20:393-394
24. Harzstark AL, Halabi S, Stadler WM et al (2013) Hypertension is associated with clinical outcome for patients (pts) with metastatic renal cell carcinoma (RCC) treated with interferon and bevacizumab on CALGB 90206. Genitourinary Cancers Symposium